. 2024 Jul 17;7(7):e2421495. doi: 10.1001/jamanetworkopen.2024.21495

Table 1. Demographics and Disease Characteristics Among Patients Receiving PP Every 6 Months at Baseline in the Double-Blind Trial.

Characteristic	Patients (N = 121)^a
Age, y^b	38.6 (11.24)
Sex, No. (%)
Female	38 (31.4)
Male	83 (68.6)
Baseline BMI	27.9 (4.84)
Age at first diagnosis of schizophrenia, y	27.5 (9.21)
Duration of illness, y	11.0 (9.45)
Duration of psychiatric hospitalization prior to study entry, d^c	61.0 (43.08)
PANSS score^d	53.4 (9.72)
PSP score^e	68.7 (12.10)
CGI-S score^f	3.0 (0.77)
Previous medication, No. (%)
Oral antipsychotic with reason to change	101 (83.5)
Long-acting injectable	20 (16.5)

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CGI-S, Clinical Global Impression–Severity scale; PANSS, Positive and Negative Syndrome Scale; PP, paliperidone palmitate; PSP, Personal and Social Performance scale.

^{^a}

Data are presented as mean (SD) unless otherwise indicated.

^{^b}

Age at screening visit.

^{^c}

A total of 47 patients had psychiatric hospitalization prior to study entry.

^{^d}

Score range, 30 to 210, with higher scores indicating greater symptom severity.

^{^e}

Score range, 1 to 100, with higher scores indicating better personal and social functioning.

^{^f}

Score range, 1 to 7 and baseline range 1 to 5, with higher scores indicating more severe illness.